Quick Answer
Vaxcyte, Inc. reported Cash and Equivalents of $173.96 million for fiscal year 2025.
Vaxcyte, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $173.96M | -55.2% |
| 2024 | $387.88M | -2.4% |
| 2023 | $397.45M | -52.4% |
| 2022 | $834.66M | +1109.9% |
| 2021 | $68.98M | -82.1% |
| 2020 | $386.20M | +554.8% |
| 2019 | $58.98M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $281.08M | -73.2% | -8.4% |
| June 30, 2025 | $306.74M | -40.9% | -11.6% |
| March 31, 2025 | $346.85M | -43.3% | -10.6% |
| December 31, 2024 | $387.88M | -2.4% | -63.1% |
| September 30, 2024 | $1.05B | +92.6% | +102.5% |
| June 30, 2024 | $518.67M | -2.3% | -15.2% |
| March 31, 2024 | $611.51M | +60.7% | +53.9% |
| December 31, 2023 | $397.45M | -52.4% | -27.1% |
- Vaxcyte, Inc. showed a decrease of -55.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Vaxcyte, Inc.’s cash and equivalents has grown by 195.0% (from $58.98 million to $173.96 million).
- The most recent figure is from Vaxcyte, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: